Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Organoids and organs-on-chips (OoCs) are rapidly evolving technologies for creating miniature human tissue models. They can mimic complex physiological functions and pathological conditions, offering more realistic platforms for disease modeling, drug screening, precision medicine, and regenerative therapies. The passing of the FDA Modernization Act 2.0 has reduced animal testing requirements for drug trials, marking a significant milestone in using advanced in vitro models such as organoids and OoCs for therapeutic discovery. Apart from technical and ethical challenges, regulatory issues persist in ensuring the reliability, scientificity, and applicability of these models in drug development. This perspective explores the concept, advancements, pros and cons, and applications of organoids and OoCs, particularly in drug research and development. It also examines global regulatory agencies' policies and actions on using these models in drug evaluation, aiming to guide industry standard setting and advance regulatory science.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2025.100667 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advanced strategies in organoid/organ-on-a-chip for food safety and nutrition.
Food Res Int
November 2025
Medical School of Nantong University, Nantong 226001, China. Electronic address:
Food nutrition and safety are fundamental to the food industry, and the development of appropriate research models is crucial. Unlike traditional animal models, the innovative organoid/organ-on-a-chip model possess distinct human-like characteristics and genomic stability, which have garnered significant attention in food research. In this review, we conduct a comparative analysis between organoids and traditional animal and 2D cell models.
View Article and Find Full Text PDFProtective effect of osmanthus water extract on liver dysfunction caused by DBP based on organoids and organ chips technologies.
Food Res Int
November 2025
Key Laboratory of Environmental Related Diseases and One Health, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, China. Electronic address:
This study aimed to investigate the protective mechanism of Osmanthus fragrans water extract (OSF) against liver injury induced by dibutyl phthalate (DBP). We utilized liver organoids and liver organ chip technology to replicate the liver microenvironment in vivo. Metabolomic analysis revealed that DBP induced oxidative stress and lipid metabolism disorders; however, following intervention with OSF, the associated abnormal metabolites were significantly reduced.
View Article and Find Full Text PDFInnovative engineering approaches to model host-microbiome interactions in vitro.
Adv Drug Deliv Rev
September 2025
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address:
The human microbiome plays a critical role in health and disease. Disruptions in microbiota composition or function have been implicated not only as markers but also as drivers of diverse pathologies, creating opportunities for targeted microbiome interventions. Advancing these therapies requires experimental models that can unravel the complex, bidirectional interactions between human tissue and microbial communities.
View Article and Find Full Text PDFHuman Small Intestinal Tissue Models to Assess Barrier Permeability: Comparative Analysis of Caco-2 Cells, Jejunal and Duodenal Enteroid-Derived Cells, and EpiIntestinal Tissues in Membrane-Based Cultures with and Without Flow.
Bioengineering (Basel)
July 2025
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.
Accurate in vitro models of intestinal permeability are essential for predicting oral drug absorption. Standard models like Caco-2 cells have well-known limitations, including lack of segment-specific physiology, but are widely used. Emerging models such as organoid-derived monolayers and microphysiological systems (MPS) offer enhanced physiological relevance but require comparative validation.
View Article and Find Full Text PDFIntegrating tumor macroenvironment, microenvironment and mechanobiology with organoid and organ-on-a-chip models for lung cancer immunotherapy.
Lung Cancer
September 2025
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea. Electronic address:
Lung cancer remains the leading cause of cancer-related mortality, and immune checkpoint inhibitors (ICIs) have revolutionized its treatment. However, immunotherapy responses vary significantly among patients, and adverse effects, such as immune-related pneumonitis, pose clinical challenges. Both the tumor macroenvironment (TMaE) and tumor microenvironment (TME) play pivotal roles in modulating immunotherapy outcomes; however, the complex crosstalk between them remains insufficiently characterized.
View Article and Find Full Text PDF